Who
Gary K. Lee
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Lyell Immunopharma.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $159K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Feb 2022
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $23K1,457 at $15.54 | filing |
| 21 Aug 2026filed 25 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $23K1,457 at $15.54 | filing |
| 10 Aug 2026filed 11 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $1,879131 at $14.34 | filing |
| 10 Aug 2026filed 11 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $1,879131 at $14.34 | filing |
| 11 May 2026filed 15 Jun 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $2,460130 at $18.92 | filing |
| 11 May 2026filed 15 Jun 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $2,460130 at $18.92 | filing |
| 11 Feb 2026filed 12 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $39K1,671 at $23.39 | filing |
| 11 Feb 2026filed 12 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $39K1,671 at $23.39 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $3,399147 at $23.12 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $3,399147 at $23.12 | filing |
| 9 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 10 Nov 2025filed 12 Nov 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $2,230138 at $16.16 | filing |
| 27 Oct 2025filed 29 Oct 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 21 Aug 2025filed 22 Aug 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $15K1,453 at $10.54 | filing |
| 20 Aug 2025filed 22 Aug 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 12 Aug 2025filed 13 Aug 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $1,406136 at $10.34 | filing |
| 11 Aug 2025filed 13 Aug 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $1,379131 at $10.53 | filing |
News
Lyell Immunopharma (NASDAQ:LYEL) versus Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Critical ComparisonLYEL · themarketsdaily.com · 20 Oct 2026Reviewing Neuphoria Therapeutics (NASDAQ:NEUP) & Lyell Immunopharma (NASDAQ:LYEL)LYEL · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Gary K. Lee; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.